Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou,Robert W. Myers,Ying Li,Yuli Chen,Xiaolan Shen,Judy Fenyk-Melody,Margaret Wu,John Ventre,Thomas W. Doebber,Nobuharu Fujii,Nicolas Musi,Michael F. Hirshman,Laurie J. Goodyear,David E. Moller +13 more
TLDR
It is reported that metformin activates AMPK in hepatocytes; as a result, acetyl-CoA carboxylase (ACC) activity is reduced, fatty acid oxidation is induced, and expression of lipogenic enzymes is suppressed.Abstract:
Metformin is a widely used drug for treatment of type 2 diabetes with no defined cellular mechanism of action. Its glucose-lowering effect results from decreased hepatic glucose production and increased glucose utilization. Metformin's beneficial effects on circulating lipids have been linked to reduced fatty liver. AMP-activated protein kinase (AMPK) is a major cellular regulator of lipid and glucose metabolism. Here we report that metformin activates AMPK in hepatocytes; as a result, acetyl-CoA carboxylase (ACC) activity is reduced, fatty acid oxidation is induced, and expression of lipogenic enzymes is suppressed. Activation of AMPK by metformin or an adenosine analogue suppresses expression of SREBP-1, a key lipogenic transcription factor. In metformin-treated rats, hepatic expression of SREBP-1 (and other lipogenic) mRNAs and protein is reduced; activity of the AMPK target, ACC, is also reduced. Using a novel AMPK inhibitor, we find that AMPK activation is required for metformin's inhibitory effect on glucose production by hepatocytes. In isolated rat skeletal muscles, metformin stimulates glucose uptake coincident with AMPK activation. Activation of AMPK provides a unified explanation for the pleiotropic beneficial effects of this drug; these results also suggest that alternative means of modulating AMPK should be useful for the treatment of metabolic disorders.read more
Citations
More filters
Journal ArticleDOI
Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway.
Raogo Ouedraogo,Xiangdong Wu,Shi Qiong Xu,Lauren Fuchsel,Hiroyuki Motoshima,Kalyankar Mahadev,Kelly Hough,Rosario Scalia,Barry J. Goldstein +8 more
TL;DR: Full-length adiponectin purified from a eukaryotic expression system suppressed ROS induced by high glucose or by treatment of endothelial cells with oxidized LDL, an effect that has implications for vascular protection in diabetes.
Journal ArticleDOI
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
Rosanne M. Crooke,Mark J. Graham,Kristina M. Lemonidis,Charles P. Whipple,Seonjoon Koo,Ranjan J. Perera +5 more
TL;DR: Findings, as well as those derived from interim phase I data with a human apoB-100 antisense drug, suggest that antisense inhibition of this target may be a safe and effective approach for the treatment of humans with hyperlipidemia.
Journal ArticleDOI
The specificities of small molecule inhibitors of the TGFß and BMP pathways
TL;DR: This study examines the specificities and potencies of the most frequently used small molecule inhibitors of the TGFß pathway and the BMP pathway against a panel of up to 123 protein kinases covering a broad spectrum of the human kinome and recommends SB-505124 as the most suitable molecule for use as an inhibitor of ALKs 4, 5 and 7 and the TMP pathway.
Journal ArticleDOI
Fructose-fed streptozotocin-injected rat: an alternative model for type 2 diabetes
TL;DR: It is demonstrated that the 10% fructose-fed followed by 40 mg/kg of BWSTZ injected rat can be a new and alternative model for T2D and higher fluid intake, blood glucose, serum lipids, liver glycogen, liver function enzymes and insulin resistance and significantly lower body weight, oral glucose tolerance, number of pancreatic β-cells and pancreaticβ-cell functions (HOMA-β) of FR10 group.
Journal ArticleDOI
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
Veronique S. Chachay,Graeme A. Macdonald,Jennifer H. Martin,Jonathan P. Whitehead,Trisha O'Moore-Sullivan,Paul Lee,Michael E. Franklin,Kerenaftali Klein,Paul J. Taylor,Maree Ferguson,Jeff S. Coombes,Gethin P. Thomas,Gary Cowin,Carl M. J. Kirkpatrick,Johannes B. Prins,Ingrid J. Hickman +15 more
TL;DR: Eight weeks administration of resveratrol did not significantly improve any features of NAFLD, compared with placebo, but it increased hepatic stress, based on observed increases in levels of liver enzymes.
References
More filters
Journal ArticleDOI
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
TL;DR: It is concluded that the drug's pharmacological effects are mediated, at least in part, through a time-dependent, self-limiting inhibition of the respiratory chain that restrains hepatic gluconeogenesis while increasing glucose utilization in peripheral tissues.
Journal ArticleDOI
The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis.
J. Denis McGarry,N. F. Brown +1 more
TL;DR: Key developments of the last 20 years that have led to the current understanding of the physiology of the CPT system, the structure of theCPT isoforms, the chromosomal localization of their respective genes, and the identification of mutations in the human population are reviewed.
Journal ArticleDOI
The AMP‐Activated Protein Kinase
D. Grahame Hardie,David Carling +1 more
TL;DR: The central hypothesis is that the AMP-activated protein kinase cascade appears to be an ancient system which evolved to protect cells against the effects of nutritional or environmental stress, and protects the cell by switching off ATP-consuming pathways and switching on alternative pathways for ATP generation.
Journal ArticleDOI
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.
Mohamad Y. El-Mir,Véronique Nogueira,Eric Fontaine,Nicole Avéret,Michel Rigoulet,Xavier Leverve +5 more
TL;DR: The results suggest the existence of a new cell-signaling pathway targeted to the respiratory chain complex I with a persistent effect after cessation of the signaling process.
Journal ArticleDOI
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
TL;DR: Metformin acts primarily by decreasing hepatic glucose output, largely by inhibiting gluconeogenesis, and also seems to induce weight loss, preferentially involving adipose tissue.